- Home
- JHI vs NTHI Comparison
JHI vs NTHI Comparison
Compare JHI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- NTHI
- Stock Information
- Founded
- JHI 1971
- NTHI 2008
- Country
- JHI United States
- NTHI United States
- Employees
- JHI N/A
- NTHI N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- NTHI Health Care
- Exchange
- JHI Nasdaq
- NTHI Nasdaq
- Market Cap
- JHI 120.3M
- NTHI 110.9M
- IPO Year
- JHI N/A
- NTHI N/A
- Fundamental
- Price
- JHI $13.86
- NTHI $4.75
- Analyst Decision
- JHI
- NTHI
- Analyst Count
- JHI 0
- NTHI 0
- Target Price
- JHI N/A
- NTHI N/A
- AVG Volume (30 Days)
- JHI 29.5K
- NTHI 269.9K
- Earning Date
- JHI 01-01-0001
- NTHI 01-01-0001
- Dividend Yield
- JHI 6.80%
- NTHI N/A
- EPS Growth
- JHI N/A
- NTHI N/A
- EPS
- JHI 1.05
- NTHI N/A
- Revenue
- JHI N/A
- NTHI $79,990.00
- Revenue This Year
- JHI N/A
- NTHI N/A
- Revenue Next Year
- JHI N/A
- NTHI N/A
- P/E Ratio
- JHI $12.47
- NTHI N/A
- Revenue Growth
- JHI N/A
- NTHI 13.52
- 52 Week Low
- JHI $11.63
- NTHI $3.20
- 52 Week High
- JHI $13.40
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- JHI 63.47
- NTHI N/A
- Support Level
- JHI $13.77
- NTHI N/A
- Resistance Level
- JHI $14.00
- NTHI N/A
- Average True Range (ATR)
- JHI 0.11
- NTHI 0.00
- MACD
- JHI 0.01
- NTHI 0.00
- Stochastic Oscillator
- JHI 74.55
- NTHI 0.00
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").